Sotrovimab drives SARS-CoV-2 Omicron variant evolution in immunocompromised patients

G. Destras, A. Bal, B. Simon, B. Lina, L. Josset
doi: https://doi.org/10.1101/2022.04.08.22273513

Article Information

doi 
https://doi.org/10.1101/2022.04.08.22273513
History 
  • April 16, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. G. Destras1,2,3,*,
  2. A. Bal1,2,3,*,
  3. B. Simon1,2,*,
  4. B. Lina1,2,3 and
  5. L. Josset1,2,3,#
  1. 1Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, F-69004, Lyon, France
  2. 2GenEPII sequencing platform, Institut des Agents Infectieux, Hospices Civils de Lyon, F-69004,Lyon, France
  3. 3CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon,Inserm,U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007,Lyon, France
  1. ↵#Corresponding author: Laurence Josset, laurence.josset{at}chu-lyon.fr, University Hospital of Lyon, France National reference center for respiratory viruses, Lyon, France, Phone: 04-72-07-10-22

  1. ↵* equal contributions

Back to top
Posted April 16, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Sotrovimab drives SARS-CoV-2 Omicron variant evolution in immunocompromised patients
G. Destras, A. Bal, B. Simon, B. Lina, L. Josset
medRxiv 2022.04.08.22273513; doi: https://doi.org/10.1101/2022.04.08.22273513
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area